bluebird bio (NASDAQ:BLUE) Now Covered by StockNews.com

Analysts at StockNews.com started coverage on shares of bluebird bio (NASDAQ:BLUE) in a research report issued on Thursday. The firm set a “sell” rating on the biotechnology company’s stock.

BLUE has been the subject of several other reports. Cantor Fitzgerald reissued a “neutral” rating on shares of bluebird bio in a research note on Monday, September 16th. Bank of America lowered bluebird bio from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $60.00 to $10.00 in a research report on Friday, November 15th. Wells Fargo & Company cut their target price on shares of bluebird bio from $60.00 to $40.00 and set an “equal weight” rating on the stock in a research report on Wednesday, September 25th. JPMorgan Chase & Co. lowered shares of bluebird bio from a “neutral” rating to an “underweight” rating in a research note on Friday, November 15th. Finally, Barclays dropped their price target on shares of bluebird bio from $80.00 to $40.00 and set an “overweight” rating for the company in a research note on Friday, November 15th. Three analysts have rated the stock with a sell rating, six have issued a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $49.14.

bluebird bio Stock Down 16.6 %

Shares of NASDAQ:BLUE opened at $6.34 on Thursday. bluebird bio has a 12 month low of $5.80 and a 12 month high of $71.60. The firm has a market cap of $1.23 billion, a P/E ratio of -3.39 and a beta of 0.72. The company has a quick ratio of 0.33, a current ratio of 0.51 and a debt-to-equity ratio of 0.37. The company’s 50-day moving average price is $8.78 and its two-hundred day moving average price is $14.11.

bluebird bio (NASDAQ:BLUE) last released its quarterly earnings results on Friday, September 13th. The biotechnology company reported ($7.20) EPS for the quarter. bluebird bio had a negative net margin of 565.74% and a negative return on equity of 322.46%. The company had revenue of $18.57 million for the quarter. As a group, research analysts forecast that bluebird bio will post -1.35 EPS for the current fiscal year.

Institutional Trading of bluebird bio

Hedge funds have recently modified their holdings of the company. Allegheny Financial Group LTD acquired a new position in bluebird bio during the second quarter valued at approximately $25,000. Verition Fund Management LLC bought a new position in shares of bluebird bio during the third quarter worth $42,000. SG Americas Securities LLC grew its holdings in shares of bluebird bio by 152.4% in the 3rd quarter. SG Americas Securities LLC now owns 122,855 shares of the biotechnology company’s stock valued at $64,000 after buying an additional 74,185 shares during the period. Price T Rowe Associates Inc. MD increased its position in shares of bluebird bio by 113.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 54,714 shares of the biotechnology company’s stock valued at $71,000 after buying an additional 29,113 shares in the last quarter. Finally, Captrust Financial Advisors raised its stake in bluebird bio by 48.2% during the 3rd quarter. Captrust Financial Advisors now owns 237,648 shares of the biotechnology company’s stock worth $123,000 after buying an additional 77,293 shares during the period. 87.43% of the stock is currently owned by institutional investors and hedge funds.

bluebird bio Company Profile

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.